Pharmacokinetic/pharmacodynamic evaluation ofivosidenib or enasidenib combined with intensive induction and consolidation chemotherapy in patients with newly diagnosed IDH1/2-mutant AML

Yue Chen1, Fang Yin2, Lei Hua3, Caroline Almon1, Salah Nabhan1, Michael Cooper2, Mohammad Hossain1, Hua Yang1, Bin Fan1

1Agios Pharmaceuticals, Inc., Cambridge, MA, USA

Email: medinfo@agios.com

Presented at the Virtual Edition of the 25th Hematology Association (EHA) Annual Congress, June 11–14, 2020

Across the table, the PM2.5 concentrations are reduced to within the range observed in healthy volunteers. The median PM2.5 concentration was within the range of 95–100%.

Methodology

• To characterize the plasma PK profiles of IVO and ENA in combination with intensive induction and consolidation chemotherapy in patients with newly diagnosed AML.

• To evaluate the PK/PD relationships of IVO and ENA in combination with intensive induction and consolidation chemotherapy in patients with newly diagnosed AML.

• To evaluate the relationships between plasma IVO/ENA PK parameters and inhibition of 2-HG at induction C1D14 in all patients.

• To evaluate the relationships between plasma IVO/ENA PK parameters and inhibition of 2-HG at induction C1D14 in all patients.

• Exploratory analyses of visit-matched plasma and bone marrow samples showed that overall, 2-HG concentrations in bone marrow correlated with those in plasma following multiple daily doses of IVO or ENA.

• Exploratory analyses of overall plasma 2-HG concentrations remained within the range observed in healthy volunteers.

• Exploratory analyses of overall plasma 2-HG concentrations remained within the range observed in healthy volunteers.

• Exploratory analyses of overall plasma 2-HG concentrations remained within the range observed in healthy volunteers.

• Exploratory analyses of overall plasma 2-HG concentrations remained within the range observed in healthy volunteers.

• Exploratory analyses of overall plasma 2-HG concentrations remained within the range observed in healthy volunteers.

• Exploratory analyses of overall plasma 2-HG concentrations remained within the range observed in healthy volunteers.

• Exploratory analyses of overall plasma 2-HG concentrations remained within the range observed in healthy volunteers.